GAMA
MRTX

Graticule Asia Macro Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-36,043
Closed -$1.24M – 200
2015
Q3 		$1.24M Buy
+36,043
New +$1.09M 0.14% 65

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Graticule Asia Macro Advisors's MRTX Position: Q4 2015 in Review

Graticule Asia Macro Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2015, closing a stake of 36,043 shares — an estimated $1.24M sold.

Graticule Asia Macro Advisors first reported a position in MRTX in Q3 2015 and held it in 1 quarter. The position peaked at $1.24M in Q3 2015. 80 funds tracked by Wall St. Rank hold MRTX as of Q4 2015.

  • Graticule Asia Macro Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 36,043 Mirati Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $1.24M.
  • Graticule Asia Macro Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $1.24M in Q3 2015.
  • 80 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.